- Home
- BDRX vs ENTO Comparison
BDRX vs ENTO Comparison
Compare BDRX & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ENTO
- Stock Information
- Founded
- BDRX 2000
- ENTO 2014
- Country
- BDRX United Kingdom
- ENTO United States
- Employees
- BDRX N/A
- ENTO N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- ENTO Health Care
- Exchange
- BDRX Nasdaq
- ENTO Nasdaq
- Market Cap
- BDRX 2.4M
- ENTO 2.5M
- IPO Year
- BDRX N/A
- ENTO 2016
- Fundamental
- Price
- BDRX $1.54
- ENTO $0.41
- Analyst Decision
- BDRX
- ENTO
- Analyst Count
- BDRX 0
- ENTO 0
- Target Price
- BDRX N/A
- ENTO N/A
- AVG Volume (30 Days)
- BDRX 3.5M
- ENTO 98.4K
- Earning Date
- BDRX 04-21-2025
- ENTO 05-20-2025
- Dividend Yield
- BDRX N/A
- ENTO N/A
- EPS Growth
- BDRX N/A
- ENTO N/A
- EPS
- BDRX N/A
- ENTO N/A
- Revenue
- BDRX $104,895.00
- ENTO N/A
- Revenue This Year
- BDRX N/A
- ENTO N/A
- Revenue Next Year
- BDRX N/A
- ENTO N/A
- P/E Ratio
- BDRX N/A
- ENTO N/A
- Revenue Growth
- BDRX N/A
- ENTO N/A
- 52 Week Low
- BDRX $1.14
- ENTO $0.19
- 52 Week High
- BDRX $74.00
- ENTO $4.23
- Technical
- Relative Strength Index (RSI)
- BDRX 35.57
- ENTO 37.79
- Support Level
- BDRX $1.14
- ENTO $0.39
- Resistance Level
- BDRX $2.65
- ENTO $0.61
- Average True Range (ATR)
- BDRX 0.24
- ENTO 0.07
- MACD
- BDRX 0.01
- ENTO -0.01
- Stochastic Oscillator
- BDRX 26.49
- ENTO 8.93
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.